Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 77c
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Join SI Premium – FREE
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.77).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Infleqtion raises Q2 revenue to $13.5M after contract restatement
- Citi raises Salesforce price target to $204, keeps Neutral rating
- BNP Paribas Exane Downgrades Lanxess AG (LXS:GR) (LNXSF) to Underperform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
